We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology IndexSM. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common s... The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology IndexSM. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of small, mid and large capitalization companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. Show more
http://www.fool.com/investing/general/2015/12/07/alnylam-pharmaceuticals-is-selling-off-today-heres.aspx?source=eptadnlnk0000002&utm_source=advfn&utm_medium=cpc&utm_campaign=investorshub
http://www.fool.com/investing/general/2015/11/01/the-top-3-biotech-etfs-on-the-market.aspx?source=eptadnlnk0000002&utm_source=advfn&utm_medium=cpc&utm_campaign=investorshub
With ever-increasing health care spending and insatiable demand for new drugs, the biotechnology sector looks poised for good growth going forward. Furthermore, the U.S. biotech sector...
The biotechnology sector has been a strong performer for much of 2013. The space has seen huge gains over and above that of the broad market, with biotech benchmarks outpacing the S&P 500...
California-based Gilead Sciences (GILD) was in focus last week as it saw some encouraging clinical trial data on its HIV pill—TAF. This report pushed up GILD by about 4.5% last week and...
In the current uncertain economic environment with ultra low interest rates, investors have been starved for income in 2012. Investors in search of a decent level of current income have...
With the economy poised to jump over the fiscal cliff in just a few days, investors are becoming all the more cautious as the risks are high for the U.S. economy to slip into another recession...
With the election over, many investors assumed that one of the key risk events for U.S. markets was past us. However, this certainly hasn’t been the case, as the election worries were...
In the last five years, investors have witnessed a variety of market conditions. Stocks were relatively strong in the middle part of 2007 but, as we all know, proceeded to fall apart during the...
Recent earnings reports from a few bellwethers in the pharmaceutical space suggest that more pain is likely ahead for the beleaguered industry. Both Pfizer (PFE) and Eli Lilly (LLY) managed to...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.5801 | 0.346535244922 | 167.4 | 168.5371 | 164.26 | 27648 | 165.95137668 | SP |
| 4 | -6.4499 | -3.69770108353 | 174.43 | 177.2578 | 162.15 | 24293 | 169.62547068 | SP |
| 12 | -1.8299 | -1.07761615924 | 169.81 | 179.67 | 159.83 | 27453 | 170.57475061 | SP |
| 26 | 14.6601 | 9.56176624054 | 153.32 | 179.67 | 151.835 | 26539 | 168.78861056 | SP |
| 52 | 8.5201 | 5.34309544713 | 159.46 | 179.67 | 140.36 | 26775 | 159.97508701 | SP |
| 156 | 5.8301 | 3.59549799568 | 162.15 | 179.67 | 121.6785 | 35083 | 150.43122332 | SP |
| 260 | 22.0801 | 15.1337217272 | 145.9 | 186.5106 | 108.08 | 50970 | 154.96988139 | SP |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
